Current Report Filing (8-k)
15 December 2022 - 09:01AM
Edgar (US Regulatory)
0001321834 false 0001321834 2022-12-14
2022-12-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
December 14, 2022
MyMD Pharmaceuticals, Inc.
(Exact
name of Registrant as specified in its charter)
|
New Jersey |
|
001-36268 |
|
22-2983783 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
No.)
|
|
(IRS
Employer
Identification
No.)
|
MyMD Pharmaceuticals, Inc.
855 N. Wolfe Street,
Suite 623
Baltimore,
MD
21205
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code:
(856)
848-8698
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
Registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common stock, no par value per share |
|
MYMD |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07 Submission of Matters to a Vote of Security
Holders.
On
December 14, 2022, MyMD Pharmaceuticals, Inc. (the “Company”) held
its 2022 annual meeting of stockholders (the “Annual Meeting”). At
the Company’s Annual Meeting, holders of the Company’s voting
securities with a total aggregate voting power of 30,840,727 votes
were present in person or represented by proxy. The matters
submitted for a vote and the related results are set forth
below.
|
|
(1) |
Election
of six (6) directors to hold office for a one year term and until
their successors are elected and qualified or until their earlier
incapacity, removal or resignation: |
|
Nominee |
|
Votes
For |
|
Votes
Withheld |
|
Broker
Non-Votes |
| Chris
Chapman |
|
19,923,914 |
|
287,893 |
|
10,628,920 |
| Craig
Eagle |
|
20,115,061 |
|
96,746 |
|
10,628,920 |
| Christopher
C. Schreiber |
|
20,066,262 |
|
145,545 |
|
10,628,920 |
| Joshua
Silverman |
|
18,720,289 |
|
1,491,518 |
|
10,628,920 |
| Jude
Uzonwanne |
|
17,816,077 |
|
2,395,730 |
|
10,628,920 |
| Bill
J. White |
|
20,157,803 |
|
54,004 |
|
10,628,920 |
The
terms of the Company’s directors were scheduled to expire at the
Annual Meeting, and the Board nominated all six directors for
re-election at the Annual Meeting. At the Annual Meeting, Dr. Chris
Chapman, Dr. Craig Eagle, Mr. Christopher C. Schreiber, Mr. Joshua
Silverman, Mr. Jude Uzonwanne, and Mr. Bill J. White were elected
as directors of the Board to serve for a term expiring at the
Company’s 2023 annual meeting of stockholders.
|
|
(2) |
Ratification
of the appointment of Morison Cogen LLP as the Company’s
independent registered public accounting firm for the fiscal year
ending December 31, 2022: |
|
Votes
For |
|
Votes
Against |
|
Votes
Abstaining |
|
30,778,525 |
|
40,617 |
|
21,585 |
For
more information about the foregoing proposals, see the Company’s
definitive proxy statement for the Annual Meeting, filed with the
Securities and Exchange Commission on October 26, 2022, the
relevant portions of which are incorporated herein by
reference.
The
results reported above are final voting results. No other matters
were considered or voted upon at the Annual Meeting.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
MYMD PHARMACEUTICALS, INC. |
|
|
|
|
|
Date:
December 14, 2022 |
By: |
/s/
Chris Chapman |
| |
|
Chris
Chapman, M.D. |
| |
|
President |
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Feb 2023 to Mar 2023
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2022 to Mar 2023
